+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

South Africa Central Nervous System Therapeutic Market to 2027 - Regional Analysis and Forecasts by Disease Type; Drug Type; Distribution Channel and Geography

  • PDF Icon

    Report

  • 76 Pages
  • September 2019
  • Region: South Africa
  • The Insight Partners
  • ID: 4847176
The South Africa Central Nervous System (CNS) Therapeutic market is expected to reach US$ 3,686.91 Mn in 2027 from US$ 2,267.59 Mn in 2018. The market is estimated to grow with a CAGR of 5.6% from 2019-2027.

Rising prevalence of CNS diseases such as malnutrition, malaria, the human immunodeficiency virus & the acquired immune deficiency syndrome (HIV/AIDS), and demographic transitions are expected to surge the market growth. However, high cost of treatment is likely to have a negative impact on the growth of the market in the coming years.

According to a data of NCBI in 2014, approximately one in three South Africans will undergo a mental disorder in a lifetime, and the prevalence is higher than various low- and middle-income countries. Moreover, as per the data of South African Journal of Psychiatry, published in 2017, in a South African population-based national study, states that the prevalence of drug use was 3.7%. The highest prevalence was for cannabis, which was 3.3%, followed by sedatives or sleeping pills to be 0.8%, amphetamine-type stimulants around 0.7% and hallucinogens, to be 0.5%. Furthermore, HIV-associated dementia (HAD) is dominant in 15-30% of untreated adults with late-stage disease. The elderly patients, who previously have an increased risk of non-AIDS related dementias, are more prone to untreated HIV. Such a rising prevalence of CNS disorders is expected to create a demand for the central nervous system (CNS) therapeutic across the world.

South Africa Central Nervous System (CNS) Therapeutic market, based on Disease Type was segmented into Neurovascular Diseases, Degenerative Disorders, Mental Health, Trauma, Others). Moreover, the Degenerative Disorders segment held largest market share owing to increasing cases of diseases. . In 2016, according to World Health Organization (WHO), it was estimated that 6.1 million individuals worldwide had Parkinson's disease, and in South Africa, around three percent of the population (50 million) suffers from the disease.

South Africa central nervous system (CNS) therapeutic market, based on drug type was segmented into analgesics, nervous system drugs, anesthetics, anti-parkinson drugs, anti-epileptics, others. Moreover, analgesics segment is expected to grow at the fastest rate during the coming years because they are used to relive pain which provides relief to patients without being consciousness.

South Africa Central Nervous System (CNS) Therapeutic market, based on Distribution Channel was segmented into Hospital Pharmacies, Retail Pharmacies. In 2018, the hospitals segment held the largest share of the market, by Distribution Channel. Moreover, same segment is expected to grow at the fastest rate during the coming years because In hospitals, therapy and treatments of patients can be performed under one roof, which minimizes the need to visit pharmacies and thereby increasing the utilization of hospital settings.

Reasons to Buy
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the central nervous system therapeutics market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the central nervous system therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table of Contents

1. Introduction
1.1 Scope of the Study
1.2 Report Guidance
1.3 Market Segmentation
2. South Africa Central Nervous System (CNS) Therapeutic Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South Africa Central Nervous System (CNS) Therapeutic Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 South Africa PEST Analysis
4.3 Expert Opinions
5. Central Nervous System (CNS) Therapeutic Market - Key Industry Dynamics
5.1 Key Market Drivers
5.1.1 Rising Prevalence of CNS Disorders
5.2 Key Market Restraints
5.2.1 High Cost of Treatment
5.3 Key Market Opportunities
5.3.1 Increase in Geriatric Population And Associated Diseases
5.4 Future Trends
5.4.1 Increasing Wearable Devices for Central Nervous System (CNS)
5.5 Impact Analysis
6. South Africa Central Nervous System (CNS) Therapeutic Market - South Africa Market Analysis
6.1 Overview
6.2 South Africa Central Nervous System (CNS) Therapeutic Market - Revenue Forecasts and Analysis - 2018- 2027
7. South Africa Central Nervous System (CNS) Therapeutic Market Analysis- by Disease Type
7.1 Overview
7.2 South Africa Central Nervous System (CNS) Therapeutic Market, By Disease Type 2018 & 2027 (%)
7.3 Neurovascular Diseases Market
7.3.1 Overview
7.3.2 South Africa Neurovascular Diseases Market Revenue and Forecasts to 2027 (US$ Mn)
7.4 Degenerative Disorders Market
7.4.1 Overview
7.4.2 South Africa Degenerative Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
7.5 Mental Health Market
7.5.1 Overview
7.5.2 South Africa Mental Health Market Revenue and Forecasts to 2027 (US$ Mn)
7.6 Trauma Market
7.6.1 Overview
7.6.2 South Africa Trauma Market Revenue and Forecasts to 2027 (US$ Mn)
7.7 Others Market
7.7.1 Overview
7.7.2 South Africa Others Market Revenue and Forecasts to 2027 (US$ Mn)
8. South Africa Central Nervous System (CNS) Therapeutic Market Analysis- by Drug Type
8.1 Overview
8.2 South Africa Central Nervous System (CNS) Therapeutic Market, By Drug Type 2018 & 2027 (%)
8.3 Analgesics Market
8.3.1 Overview
8.3.2 South Africa Analgesics Market Revenue and Forecasts to 2027 (US$ Mn)
8.4 Anesthetics Market
8.4.1 Overview
8.4.2 South Africa Anesthetics Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 Anti-Parkinson Drugs Market
8.5.1 Overview
8.5.2 South Africa Anti-Parkinson Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
8.6 Anti-Epileptics Drugs Market
8.6.1 Overview
8.6.2 South Africa Anti-Epileptics Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
8.7 Others Drugs Market
8.7.1 Overview
8.7.2 South Africa Others Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
9. South Africa Central Nervous System (CNS) Therapeutic Market Analysis- by Distribution Channel
9.1.1 Overview
9.1.2 South Africa Central Nervous System (CNS) Therapeutic Market, By Distribution Channel 2018 & 2027 (%)
9.1.3 Hospital Pharmacies Market
9.1.4 Overview
9.1.5 South Africa Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.6 Retail Pharmacies Market
9.1.6.1 Overview
9.1.6.2 South Africa Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
10. Central Nervous System (CNS) Therapeutic Market - Industry Landscape
10.1 Overview
10.2 Growth Strategies done by the companies in the Market, (%)
10.3 Organic Developments
10.3.1 Overview
10.4 Inorganic developments
10.4.1 Overview
11. Central Nervous System (CNS) Therapeutic Market-Key Company Profiles
11.1 Eli Lilly and company
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Financial Overview
11.1.4 Product Portfolio
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Pfizer Inc.
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Financial Overview
11.2.4 Product Portfolio
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Merck & Co., Inc.
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Financial Overview
11.3.4 Product Portfolio
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 AstraZeneca
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Financial Overview
11.4.4 Product Portfolio
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Novartis AG
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Financial Information
11.5.4 Product Portfolio
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Takeda Pharmaceutical Company Limited
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Financial Information
11.6.4 Product Pipeline
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Teva Pharmaceutical Industries Ltd.
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Financial Overview
11.7.4 Product Portfolio
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Lundbeck
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Financial Overview
11.8.4 Product Portfolio
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Adcock Ingram
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Financial Overview
11.9.4 Product Portfolio
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Lupin Limited
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Financial Information
11.10.4 Product Portfolio
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About The Publisher
12.2 Glossary of Terms

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Eli Lilly and company
  • Pfizer Inc.
  • Merck & Co., Inc.
  • AstraZeneca
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Lundbeck
  • Adcock Ingram
  • Lupin Limited